Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (cv-6504) against established murine adenocarcinomas (mac)

ABSTRACT 2,3,5-Trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504), an inhibitor of 5-lipoxygenase and thromboxane A2 synthase and a scavenger of active oxygen species, has been shown to

exhibit profound anti-tumour activity against three established murine adenocarcinomas (MACs) that are generally refractory to standard cytotoxic agents. For the cachexia-inducing MAC16

tumour, optimal anti-tumour activity was seen at dose levels of 10 and 25 mg kg-1 day-1, together with a reversal of cachexia and a doubling of the time to sacrifice of the animals through

cachexia from 8 days to 17 days. The remaining tumour fragments showed extensive necrosis in regions distal from the blood supply. Growth of the MAC13 tumour was also effectively suppressed

at dose levels between 5 and 50 mg kg-1 day-1, resulting in a specific growth delay between 1.0 and 1.2. Growth of the MAC26 tumour was also inhibited a concentration-related manner, with

doses of 25-50 mg kg-1 day-1 being optimal. Anti-tumour activity towards all three tumours at low dose levels of CV-6504 was effectively suppressed by concurrent administration of linoleic

acid (1 g kg-1 day-1), suggesting that inhibition of linoleate metabolism was responsible for the anti-tumour effect. Tumour sensitivity may be correlated with increased DT-diaphorase that

are required to metabolise CV-6504 to the active hydroquinone, which inhibits 5-lipoxygenase activity. Access through your institution Buy or subscribe This is a preview of subscription

content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue

Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL

ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS COMPARATIVE STUDY OF THE ANTI-TUMOUR

EFFECTS OF THE IMIPRIDONE, ONC201 AND ITS FLUORINATED ANALOGUES ON PANCREATIC CANCER CELL LINE Article Open access 07 May 2025 SYNERGISTIC EFFECTS OF ABIETIC ACID COMBINED WITH DOXORUBICIN

ON APOPTOSIS INDUCTION IN A HUMAN COLORECTAL CANCER CELL LINE Article Open access 08 May 2025 FRUTICULINE A, A CHEMICALLY-DEFINED DITERPENE, EXERTS ANTINEOPLASTIC EFFECTS IN VITRO AND IN

VIVO BY MULTIPLE MECHANISMS Article Open access 05 October 2020 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Pharmaceutical Sciences Institute, Aston University, Birmingham, UK HJ Hussey

Authors * HJ Hussey View author publications You can also search for this author inPubMed Google Scholar * MC Bibby View author publications You can also search for this author inPubMed 

Google Scholar * MJ Tisdale View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Hussey, H., Bibby, M. & Tisdale, M. Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas

(MAC). _Br J Cancer_ 73, 1187–1192 (1996). https://doi.org/10.1038/bjc.1996.229 Download citation * Issue Date: 01 May 1996 * DOI: https://doi.org/10.1038/bjc.1996.229 SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided

by the Springer Nature SharedIt content-sharing initiative